Asian Journal of Medical Principles and Clinical Practice

The gut microbiota, which is a group of different microbes that live in the digestive system, has a new role as an important regulator of metabolic health. This study looks at the complicated link between the microbiota in our guts and insulin resistance. It looks at the processes at play, how the composition changes, and what might happen after treatment. Dysbiosis, which is marked by a lack of variety in microbes and a mismatch between good and bad species, makes insulin resistance worse. This disease makes it harder for the body to make short-chain fatty acids (SCFAs), breaks down the barrier in the intestines, and causes inflammation all over the body. Bacteria like Akkermansia muciniphila and Faecalibacterium prausnitzii are needed to keep the metabolism steady. But when Firmicutes and Bacteroidetes levels get out of balance, as well as when endotoxin levels rise, metabolic problems get worse. Changing what you eat, working out, and using treatments that target microbiota, like prebiotics, probiotics, and fecal microbiota transplantation (FMT), may help fix the balance of microbes and lower insulin resistance. Different methods, differences in microbiota between people, and the need for standardized therapeutic treatments are some of the problems that study in this area still faces, even though it is making progress. We need to learn more about the molecular processes that happen in the gut microbiota. Future study should focus on large-scale interventional trials that last a long time. Also, personalized treatments based on the microbiome should be thought about. This review talks about how microbiome-targeted treatments might be used in real life. It also stresses the importance of gut bacteria in managing insulin resistance.